Stocks Health care BIVI

NASDAQ · Health care

Biovie Inc. (BIVI)

It posted a net loss of $22.1M. At June 30, 2026 it held $9M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on August 13, 2026.

What Biovie Inc. does

Biovie Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BIVI.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Biovie Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 14, 2026
   Material agreement 8-K
2. September 14, 2026
   Securities offering prospectus 424B5
3. September 3, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. August 19, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. August 14, 2026
   IPO registration (amended) S-1/A
6. August 13, 2026
   Annual report 10-K · period to June 30, 2026Diluted EPS -$3.05 versus -$12.12.
7. August 7, 2026
   Passive stake changed SCHEDULE 13G/A
8. August 7, 2026
   Passive stake (5% or more) SCHEDULE 13G
9. August 7, 2026
   Offering term sheet FWP
10. August 6, 2026
    Offering term sheet FWP

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 28, 2026. Insider transactions on SEC

Insider trades

What the people running Biovie Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $49.1K worth of shares on the open market in the last 90 days and sold none.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BIVI

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 26,321 shares in total, about $42.2K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BIVI

What does Biovie Inc. do?

Biovie Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BIVI.

Is Biovie Inc. profitable?

No. In fiscal 2026 it reported a net loss of $22.1M.

When did Biovie Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 14, 2026.

Similar companies

Compare BIVI with

Compare BIVI with any company

Follow BIVI

Get an email when Biovie Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BIVI: get an email when it files

Where the numbers come from

Financial figures are the values Biovie Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.